ORIGINA



Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 (703) 746-4000

or <u>Fax</u>

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1) Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 7590 04/20/2004

Melissa A Shaw Patent Department **Bayer Corporation** 800 Dwight Way P O Box 1986 Berkeley, CA 94701

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.

Jill Durante	(Depositor's name)	
fil Puante	(Signature)	
July 16, 2004	(Datc)	

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/671,773	09/27/2000	Clark Pan	MSB-7272	7437

TITLE OF INVENTION: PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP)RECEPTOR 3 (R3) AGONISTS AND THEIR PHATMACOLOGICAL METHODS OF USE

APPLN, TYPE	SMALL ENTITY	ISSUE F	EE	PUBLICATION FEE	PUBLICATION FEE TOTAL FEE(S) DUE	
nonprovisional	NO	\$1330	\$1330		\$1330	07/20/2004
EXAM	MINER	ART UN	IT	CLASS-SUBCLASS]	
MORAN, M	IARJORIE A	1631		530-324000		
CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47-Rev 03-02 or more recent) attached. Use of a Customer		2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. Susan M. Pellegrino			M. Pellegrino	
PLEASE NOTE: Unless	ed to the USPTO or is being s	low, no assignee da submitted under sep	ata will appea parate cover.	f (print or type) ar on the patent, Inclusion of as Completion of this form is NOT E: (CITY and STATE OR COU	a substitute for filing an ass	ate when an assignment has signment.

Bayer Pharmaceuticals Corporation

West Haven, Connecticut, U.S.

Please check the appropriate assignee category or categories (will not be	e printed on the patent);	☐ individual	Corporation or other private group entity	governmen 🔾		
4a. The following fee(s) are enclosed:	4b. Payment of Fee(s):					
Issue Fee Issue Fee	☐ A check in the amount of the fee(s) is enclosed.					
Publication Fee	☐ Payment by credit card. Form PTO-2038 is attached.					
☐ Advance Order - # of Copies	The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 13-3375 (enclose an extra copy of this form).					
Director for Patents is requested to apply the Issue Fee and Publication I	Fee (if any) or to re-apply	any previously	paid issue fee to the application identified abo	vc.		
NOTE; The Issue Fee and Publication Fee (if Aguired) will not be	07/16/2004 Reg. No. 48,972	<u>,</u>				
other than the applicant; a registered attorney or agent; or the assinterest as shown by the records of the United States Patent and Trader	ignee or other party in mark Office.					
This collection of information is required by 37 CFR 1.311. The inf obtain or retain a benefit by the public which is to file (and by the application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR estimated to take 12 minutes to complete, including gathering, prepar completed application form to the USPTO. Time will vary dependicase. Any comments on the amount of time you require to com suggestions for reducing this burden, should be sent to the Chief in Patent and Trademark Office, U.S. Department of Commerce, 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-145	USPTO to process) and i.14. This collection is ing, and submitting the ng upon the individual plete this form and/or formation Officer, U.S. Alexandria, Virginia TO THIS ADDRESS.					
Under the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the Paperwork Reduction Act of 1995, no persons are required for the 1995, no person	quired to respond to a		•			

Attorney Docket No. MSB 7272



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Bayer Pharmaceuticals Corporation

Group Art Unit: 1631

Serial No.:

09/671,773

Examiner: Moran, Marjorie A.

Filed:

09/27/2000

For:

Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor 3 (R3)

Agonists and Their Pharmacological Methods of Use

MAIL STOP ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Mail Stop ISSUE FEE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: July 16, 2004

ISSUE FEE TRANSMITTAL LETTER

Sir:

Enclosed please find the following documents in connection with transmittal and payment of the issue fee in the above-identified case:

- Part B Issue Fee Transmittal (Form PTOL-85B) (IN DUPLICATE); and
- Return Receipt Post Card.

Respectfully submitted,

Date: July 16, 2004

Susan M. Pellegrino

Attorney for Applicants

Reg. No. 48,972

Bayer Pharmaceuticals Corporation 400 Morgan Lane

West Haven, CT 06516-4175

Telephone: (203) 812-6450 Facsimile: (203) 812-6459